
    
      A multicenter, randomized, double-blind, placebo-controlled, dose escalation study of healthy
      female subjects at â‰¥ 40 weeks gestation and who are scheduled for induction. A
      dose-escalation portion of the study is followed by a randomized, double-blind,
      placebo-controlled portion of the study. The endpoints include cervical ripening, as well as
      progression to labor and delivery.
    
  